Differential effects of p53 mutants on the growth of human bronchial epithelial cells

Molecular Carcinogenesis

Volumn 19, Issue 3, 1997, Pages 191-203

  Coursen, Jill D ^a   Bennett, William P ^a   Khan, Mohammed A ^a   Forrester, Kathleen ^a   Pietenpol, Jennifer A ^b   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Growth arrest; Oncogenes; P53; Tumor suppressor genes

Indexed keywords

VIRUS VECTOR;

ARTICLE; BRONCHUS MUCOSA; CELL SURVIVAL; CODON; COLONY FORMING CELL; CONTROLLED STUDY; EPITHELIUM CELL CANCER; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; PRIORITY JOURNAL;

BRONCHI; CELL DIVISION; CELL LINE; CELL SURVIVAL; DNA, COMPLEMENTARY; EPITHELIAL CELLS; EPITHELIUM; GENES, P53; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

BRONCHUS;

EID: 0030790238     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199707)19:3<191::AID-MC7>3.0.CO;2-H     Document Type: Article

References (99)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancer. Science 253:49-53, 1991.
2. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 351:453-456, 1991.
3. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: A review. Int J Cancer 57:1-9, 1994.
4. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3547-3551, 1994.
5. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 55:4855-4878, 1994.
6. Harris CC. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442-1455, 1996.
7. Ko LJ, Prives C. p53: Puzzle and paradigm. Genes Dev 10:1054-1072, 1996.
8. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1287:77-102, 1996.
9. Foord OS, Bhattacharya P, Reich Z, Rotter V. A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Res 19:5191-5198, 1991.
10. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence-specific DMA-binding protein. Science 252:1708-1711, 1991.
11. EI-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1:45-49, 1992.
12. Raycroft L, Wu HY, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049-1051, 1990.
13. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046-1049, 1990.
14. Mercer WE. Cell cycle regulation and the p53 tumor suppressor protein. Crit Rev Eukaryot Gene Expr 2:251-263, 1992.
15. Kastan MB, Canman CE, Leonard CJ. p53, cell cycle control and apoptosis: Implications for cancer Cancer Metastasis Rev 14:3-15, 1995.
16. Lane DP. Cancer: A death in the life of p53. Nature 362:786-787, 1993.
17. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993.
18. Wyllie AH. Apoptosis (the 1992 Frank Rose Memorial Lecture). Br J Cancer 67:205-208, 1993.
19. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu J-R, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcriptional factor ERCC3. Proc Natl Acad Sci USA 91:2230-2234, 1994.
20. Smith ML, Chen IT, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376-1380, 1994.
21. Ford JM, Hanawalt PC. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci USA 92:8876-8880, 1995.
22. Wang XW, Yeh H, Schaeffer L, et al. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet 10:188-195, 1995.
23. Smith ML, Chen IT, Zhan Q, O'Connor PM, Fornace AJ Jr. Involvement of the p53 tumor suppressor in repair of UV-type DNA damage. Oncogene 10:1053-1059, 1995.
24. Li G, Mitchell DL, Ho VC, Reed JC, Tron VA. Decreased DNA repair but normal apoptosis in UV-irradiated skin of p53 transgenic mice. Am J Pathol 148:1113-1123, 1996.
25. Mirzayans R, Enns L, Dietrich K, Barley RD, Paterson MC. Faulty DNA polymerase delta/epsilon-mediated excision repair in response to gamma radiation or ultraviolet light in p53-deficient fibroblast strains from affected members of a cancer prone family with Li-Fraumeni syndrome. Carcinogenesis 17:691-699, 1996.
26. Liu PK, Kraus E, Wu TA, Strong LC, Tainsky MA. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations. Oncogene 12:2267-2278, 1996.
27. Khochbin S, Principaud E, Chabanas A, Lawrence JJ. Early events in murine erythroleukemia cells induced to differentiate: Accumulation and gene expression of the transformation-associated cellular protein p53. J Mol Biol 200:55-64, 1988.
28. Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wildtype p53 in pre-B-cell differentiation in vitro. Proc Natl Acad Sci USA 88:8982-8986, 1991.
29. Woodworth CD, Wang H, Simpson S, Alvarez-Salas LM, Notario V. Overexpression of wild-type p53 alters growth and differentiation of normal human keratinocytes but not human papillomavirus-expressing cell lines. Cell Growth Differ 4:367-376, 1993.
30. Radinsky R, Fidler IJ, Price JE, et al. Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene 9:1877-1883, 1994.
31. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 266:1821-1828, 1994.
32. Lane DP. p53, guardian of the genome. Nature 358:15-16, 1992.
33. Oren M. Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 5:221-227, 1994.
34. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B, Libermann DA. p53 involvement in control of G2 exit of the cell cycle: Role in DNA damage-induced apoptosis. Oncogene 10:2263-2270, 1995.
35. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689-1694, 1984.
36. Nelson WG, Kastan MB. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815-1823, 1994.
37. EI-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
38. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90-98, 1994.
39. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8:2540-2551, 1994.
40. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993.
41. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p53 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclmdependent kinases. Cell 75:805-816, 1993.
42. EI-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174, 1994.
43. Li Y, Jenkins CW, Nichols MA, Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9:2261-2268, 1994.
44. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578, 1994.
45. Pines J. Cell cycle: p21 inhibits cyclin shock. Nature 369:520-521, 1994.
46. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537, 1994.
47. Macleod KF, Sherry N, Hannon G, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9:935-944, 1995.
48. Zauberrnan A, Lupo A, Oren M. Identification of p53 target genes through immune selection of genomic DNA: The cyclin G gene contains two distinct p53 binding sites. Oncogene 10:2361-2366, 1995.
49. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 12:461-468, 1993.
50. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7:1126-1132, 1993.
51. Juven T, Barak Y, Zauberman A, George DL, Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411-3416, 1993.
52. Kastan MB, Zhan Q, EI-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597, 1992.
53. Cross SM, Sanchez CA, Morgan CA, et al. A p53-dependent mouse spindle checkpoint. Science 267:1353-1356, 1995.
54. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. Science 271:1744-1747, 1996.
55. Vahakangas KH, Samet JM, Metcalf RA, et al. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 339:576-580, 1992.
56. Sundaresan V, Ganly P, Hasleton P, et al. p53 and chromosome 3 abnormalities characteristic of malignant lung tumors are detectable in preinvasive lesions of the bronchus. Oncogene 7:1989-1997, 1992.
57. Sozzi G, Miozzo M, Donghi R, et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 52:6079-6082, 1992.
58. Bennett WP, Colby TV, Travis WD, et al. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 53:4817-4822, 1993.
59. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wildtype p53. Science 249:912-915, 1990.
60. Mercer WE, Shields MT, Amin M, et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87:6166-6170, 1990.
61. Gerwin BI, Spillare E, Forrester K, et al. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc Natl Acad Sci USA 89:2759-2763, 1992.
62. Takahashi T, Carbone D, Nau MM, et al. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52:2340-2343, 1992.
63. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 70:523-526, 1992.
64. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet 4:42-46, 1993.
65. Frebourg T, Barbier N, Kassel J, Ng Y, Romero P, Friend SH. A functional screen for germ line p53 mutations based on transcriptional activation. Cancer Res 52:6976-6978, 1992.
66. Forrester K, Lupold SE, Ott VL, et al. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10:2103-2111, 1995.
67. Reddel RR, Ke Y, Gerwin BI, et al. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res 48:1904-1909, 1988.
68. Willey JC, Broussoud A, Sleemi A, Bennett WP, Cerutti P, Harris CC. Immortalization of normal human bronchial epithelial cells by human papillomaviruses 16 or 18. Cancer Res 51:5370-5377, 1991.
69. Reddel RR, Ke Y, Kaighn ME, et al. Human bronchial epithelial cells neoplastically transformed by v-Ki-ras: Altered response to inducers of terminal squamous differentiation. Oncogene Res 3:401-408, 1988.
70. Amstad P, Reddel RR, Pfeifer A, Malan-Shibley L, Mark GE, Harris CC. Neoplastic transformation of a human bronchial epithelial cell line by a recombinant retrovirus encoding viral Harvey ras. Mol Carcinog 1:151-160, 1988.
71. Pfeifer AM, Mark GE, Malan-Shibley L, Graziano S, Amstad P, Harris CC. Cooperation of c-raf-1 and c-myc protooncogenes in the neoplastic transformation of simian virus 40 large tumor antigen-immortalized human bronchial epithelial cells. Proc Natl Acad Sci USA 86:10075-10079, 1989.
72. Pfeifer AM, Jones RT, Bowden PE, et al. Human bronchial epithelial cells transformed by the c-raf-1 and c-myc protooncogenes induce multidifferentiated carcinomas in nude mice: A model for lung carcinogenesis. Cancer Res 51:3793-3801, 1991.
73. Klein-Szanto AJP, lizasa T, Momiki S, et al. A tobacco-specific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells. Proc Nati Acad Sci USA 89:6693-6697, 1992.
74. Iazasa T, Momiki S, Bauer B, et al. Tumor development of xenotransplanted immortalized human cells after in vivo exposure to chemical carcinogens, Carcinogenesis 14:1789-1794, 1993.
75. Lechner JF, LaVeck MA. A serum-free method for culturing normal human bronchial epithelial cells at clonal density. Journal of Tissue Culture Methods 9:43-48, 1985.
76. Cepko CL, Roberts BE, Mulligan RC. Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell 37:1053-1062, 1984.
77. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33:153-159, 1983.
78. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6:2895-2902, 1986.
79. Deitch A. Cytophotometry of Nucleic Acids. Academic Press, New York, 1966.
80. Schulte E. Hematoxylin and the Feulgen reagent in nuclear staining. In: Boon ML, Kok LP (eds), Standardization and Quantitation of Diagnostic Staining in Cytology. Columbo Press, Leyden, Netherlands, 1986, pp. 15-26.
81. Mikel UV. Absolute DNA values from Feulgen microspectrophotometric measurements and quantitative electron microscope. Analytical and Quantitative Cytology and Histology 9:13-16, 1987.
82. Bacus JW, Grace LJ. Optical microscope system for standardized cell measurements and analyses. Applied Optics 26:3280-3293, 1987.
83. Hindermann W, Schulman J, Andreeff M. Convention of nomenclature for DNA cytometry. Cytometry 5:445-446, 1984.
84. Cho Y, Gorina S, Jeffrey P, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 364:346-355, 1994.
85. Hosoe S, Ueno K, Shigedo Y, et al. A frequent deletion of chromosome 5q21 in advanced small cell and non-small cell carcinoma of the lung. Cancer Res 54:1787-1790, 1994.
86. Wieland I, Bohm M. Frequent allelic deletion at a novel locus on chromosome 5 in human lung cancer. Cancer Res 54:1772-1774, 1994.
87. Fong KM, Zimmerman PV, Smith PJ. Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. Cancer Res 55:220-223, 1995.
88. D'Amico D, Carbone DP, Johnson BE, Meltzer SJ, Minna JD. Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer. Cancer Res 52:1996-1999, 1992.
89. Linardopoulos S, Gonos ES, Spandidos DA. Abnormalities of retinoblastoma gene structure in human lung tumors. Cancer Lett 71:67-74, 1993.
90. Shiseki M, Kohno T, Nishikawa R, Sameshima Y, Mizoguchi H, Yokota J. Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma. Cancer Res 54:5643-5648, 1994.
91. Shimizu E, Coxon A, Otterson GA, et al. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9:2441-2448, 1994.
92. Miller CW, Chumakov A, Said J, Chen DL, Aslo A, Koeffler HP. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 8:1815-1824, 1993.
93. Mukhopadhyay T, Roth JA. A codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53. Cancer Res 53:4362-4366, 1993.
94. Slingerland JM, Jenkins JR, Benchimol S. The transforming and suppressor functions of p53 alleles: Effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J 12:1029-1037, 1993.
95. Gollahon LS, Shay JW. Immortalization of human mammary epithelial cells transfected with mutant p53 (273his). Oncogene 12:715-725, 1996.
96. Pocard M, Chevillard S, Villaudy J, Poupon MF, Dutrillaux B, Remvikos Y. Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene 12:875-882, 1996.
97. Bond JA, Wyllie FS, Wynford-Thomas D. Escape from senescence in human diploid fibroblasts induced directly by mutant p53. Oncogene 9:1885-1889, 1994.
98. Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB. Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 8:2555-2559, 1993.
99. Wyllie FS, Lernoine NR, Barton CM, Dawson T, Bond J, WynfordThomas D. Direct growth stimulation of normal human epithelial cells by mutant p53. Mol Carcinog 7:83-88, 1993.